Preparation And Storage
Recommended Assay Procedures
For optimal and reproducible results, BD Horizon Brilliant™ Stain Buffer should be used anytime BD Horizon Brilliant™ dyes are used in a multicolor flow cytometry panel. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. When BD Horizon Brilliant Stain Buffer is used in in the multicolor panel, it should also be used in the corresponding compensation controls for all dyes to achieve the most accurate compensation. For the most accurate compensation, compensation controls created with either cells or beads should be exposed to BD Horizon Brilliant Stain Buffer for the same length of time as the corresponding multicolor panel. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).
Product Notices
- Since applications vary, each investigator should titrate the reagent to obtain optimal results.
- An isotype control should be used at the same concentration as the antibody of interest.
- Source of all serum proteins is from USDA inspected abattoirs located in the United States.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
- Pacific Blue™ is a trademark of Molecular Probes, Inc., Eugene, OR.
- BD Horizon Brilliant Violet 421 is covered by one or more of the following US patents: 8,158,444; 8,362,193; 8,575,303; 8,354,239.
- BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
Companion Products
The R12-31 monoclonal antibody specifically recognizes Receptor activator of NF-KB (RANK) which is also known as CD265, TNF-related activation-induced cytokine receptor (TRANCE Receptor/TRANCE-R), Osteoclast differentiation factor receptor (ODFR), or Ly109. CD265 (RANK) is a type I transmembrane glycoprotein that is encoded by Tnfrsf11a (Tumor necrosis factor receptor superfamily member 11a). CD265 (RANK) is expressed by cells in various tissues including osteoclasts and dendritic cells. CD265 (RANK) serves as the signaling receptor for RANKL (CD254/TRANCE) and regulates the activation and differentiation of osteoclasts. Signaling through the RANK:RANKL interaction also increases the survival of dendritic cells and their antigen presentation function to T cells.
Development References (3)
-
Habbeddine M, Verthuy C, Rastoin O, et al. Receptor Activator of NF-kappaB Orchestrates Activation of Antiviral Memory CD8 T Cells in the Spleen Marginal Zone. Cell Rep. 2017; 21(9):2515-2527. (Clone-specific: Flow cytometry). View Reference
-
Hakozaki A, Yoda M, Tohmonda T, et al. Receptor activator of NF-kappaB (RANK) ligand induces ectodomain shedding of RANK in murine RAW264.7 macrophages. J Immunol. 2010; 184(5):2442-2448. (Clone-specific: Flow cytometry). View Reference
-
Kamijo S, Nakajima A, Ikeda K et al. Amelioration of bone loss in collagen-induced arthritis by neutralizing anti-RANKL monoclonal antibody. Biochem Biophys Res Commun. 2006; 347(1):124-132. (Immunogen: Flow cytometry). View Reference
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.